Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2018 December;109(6) > Minerva Medica 2018 December;109(6):410-7

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   

Minerva Medica 2018 December;109(6):410-7

DOI: 10.23736/S0026-4806.18.05774-9

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Management of primary biliary cholangitis prior to obeticholic acid availability

Marilena DURAZZO 1 , Silvia BONETTO 1, Sharmila FAGOONEE 2, Anna MORGANDO 3, Rinaldo PELLICANO 3

1 Department of Medical Sciences, University of Turin, Turin, Italy; 2 Institute for Biostructures and Bioimages (CNR) c/o Molecular Biotechnology Center, Turin, Italy; 3 Unit of Gastroenterology, Molinette-SGAS Hospital, Turin, Italy



BACKGROUND: Primary biliary cholangitis (PBC) is an autoimmune cholestatic liver disease with unknown etiology. The prognosis of patients affected by PBC is heterogeneous, with a relevant improvement achieved after the introduction of ursodeoxycolic acid (UDCA). Since in the last years obeticholic acid (OCA) has been approved for the combined treatment of PBC, in patient non-responders to UDCA or as monotherapy in those intolerant to UDCA, we evaluated the response to UDCA in a cohort of patients with PBC managed in a specialistic setting.
METHODS: We included 38 UCDA-treated non-cirrhotic, early-PBC patients. Data were retrieved from documents compiled during the annual follow-up. The response to therapy was assessed comparing the parameters of our cohort with the inclusion criteria of the POISE Trial and the Paris I and Paris II criteria.
RESULTS: The cohort included 34/38 female patients and the average age was 65.34±10.69 years. Over 50% of the patients were affected by at least one disease associated to PBC. Using the POISE criteria and the Paris I and Paris II criteria, we identified 5, 2 and 5 non-responders, respectively. All patients with severe fibrosis had a biochemical response to UDCA according to the three different criteria applied. No side effect was reported.
CONCLUSIONS: We confirm that UDCA is a safe and effective treatment in patients with PBC. Non-responder patients represent 13% of our population, with high risk of disease progression and complications. In this context, further therapy using OCA should be considered.


KEY WORDS: Liver cirrhosis, biliary - Obeticholic acid - Therapeutics

inizio pagina